Literature DB >> 3729334

Conversion of 5-fluorocytosine to 5-fluorouracil by human intestinal microflora.

B E Harris, B W Manning, T W Federle, R B Diasio.   

Abstract

The mechanism of toxicity from 5-fluorocytosine chemotherapy is unclear. However, recent evidence suggests that the generation of 5-fluorouracil by a host may play an important role in the development of this toxicity. Using an in vitro semicontinuous culture system to mimic the intestinal microflora, we examined the capacity of this complex microbial community to convert 5-fluorocytosine to 5-fluorouracil. The system was dosed initially and after 2 weeks of chronic exposure to 5-fluorocytosine with radiolabeled 5-fluorocytosine. No detectable production of 5-fluorouracil was observed up to 8 h after the acute dose; however, at 24 h and at all time points thereafter, increasing levels of 5-fluorouracil were detected for 4 days. The chronic dose resulted in an increased rate of 5-fluorouracil production without the 8-h lag time. These findings suggest that the enzyme or enzymes responsible for the deamination of 5-fluorocytosine to 5-fluorouracil by the intestinal microflora can be induced by chronic exposure to 5-fluorocytosine and that this conversion may provide a mechanism through which 5-fluorocytosine toxicity is manifested.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3729334      PMCID: PMC180361          DOI: 10.1128/AAC.29.1.44

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

1.  Therapy of cryptococcosis with a combination of flucytosine and amphotericin B.

Authors:  J P Utz; I L Garriques; M A Sande; J F Warner; G L Mandell; R F McGehee; R J Duma; S Shadomy
Journal:  J Infect Dis       Date:  1975-10       Impact factor: 5.226

2.  COMPOSITION, ALTERATION, AND EFFECTS OF THE INTESTINAL FLORA.

Authors:  R DUOBOS; R W SCHAEDLER; R COSTELLO
Journal:  Fed Proc       Date:  1963 Nov-Dec

Review 3.  Metabolism of foreign compounds by gastrointestinal microorganisms.

Authors:  R R Scheline
Journal:  Pharmacol Rev       Date:  1973-12       Impact factor: 25.468

4.  Flucytosine. An effective oral treatment for chromomycosis.

Authors:  A A Mauceri; S I Cullen; A G Vandevelde; J E Johnson
Journal:  Arch Dermatol       Date:  1974-06

5.  Determination of organic acids of low relative molecular mass (C1 to C4) in dilute aqueous solution.

Authors:  P O Bethge; K Lindström
Journal:  Analyst       Date:  1974-02       Impact factor: 4.616

Review 6.  Pyrimidine metabolism in microorganisms.

Authors:  G A O'Donovan; J Neuhard
Journal:  Bacteriol Rev       Date:  1970-09

7.  Mode of action of 5-fluorocytosine and mechanisms of resistance.

Authors:  A Polak; H J Scholer
Journal:  Chemotherapy       Date:  1975       Impact factor: 2.544

8.  Metabolic studies with 5-fluorocytosine-6-14C in mouse, rat, rabbit, dog and man.

Authors:  A Polak; E Eschenhof; M Fernex; H J Scholer
Journal:  Chemotherapy       Date:  1976       Impact factor: 2.544

9.  Metabolism of the benzidine-based azo dye Direct Black 38 by human intestinal microbiota.

Authors:  B W Manning; C E Cerniglia; T W Federle
Journal:  Appl Environ Microbiol       Date:  1985-07       Impact factor: 4.792

10.  Experimental therapy of cladosporiosis and sporotrichosis with 5-fluorocytosine.

Authors:  E R Block; A E Jennings; J E Bennett
Journal:  Antimicrob Agents Chemother       Date:  1973-01       Impact factor: 5.191

View more
  30 in total

1.  Validation of an isocratic HPLC method to detect 2-fluoro-beta-alanine for the analysis of dihydropyrimidine dehydrogenase activity.

Authors:  Kinta M Serve; Jennifer L Darnell; Jody K Takemoto; Neal M Davies; Margaret E Black
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2010-05-19       Impact factor: 3.205

Review 2.  Gut microbiome interactions with drug metabolism, efficacy, and toxicity.

Authors:  Ian D Wilson; Jeremy K Nicholson
Journal:  Transl Res       Date:  2016-08-13       Impact factor: 7.012

3.  Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis.

Authors:  Annemarie E Brouwer; Hendrikus J M van Kan; Elizabeth Johnson; Adul Rajanuwong; Prapit Teparrukkul; Vannaporn Wuthiekanun; Wirongrong Chierakul; Nick Day; Thomas S Harrison
Journal:  Antimicrob Agents Chemother       Date:  2006-12-28       Impact factor: 5.191

4.  Metabolism of 6-nitrochrysene by intestinal microflora.

Authors:  B W Manning; W L Campbell; W Franklin; K B Delclos; C E Cerniglia
Journal:  Appl Environ Microbiol       Date:  1988-01       Impact factor: 4.792

Review 5.  Developing a metagenomic view of xenobiotic metabolism.

Authors:  Henry J Haiser; Peter J Turnbaugh
Journal:  Pharmacol Res       Date:  2012-08-09       Impact factor: 7.658

6.  Flucytosine conversion to fluorouracil in humans: does a correlation with gut flora status exist? A report of two cases using fluorine-19 magnetic resonance spectroscopy.

Authors:  M C Malet-Martino; R Martino; M de Forni; A Andremont; O Hartmann; J P Armand
Journal:  Infection       Date:  1991 May-Jun       Impact factor: 3.553

7.  19F nuclear magnetic resonance study of fluoropyrimidine metabolism in strains of Candida glabrata with specific defects in pyrimidine metabolism.

Authors:  M O Fasoli; D Kerridge; P G Morris; A Torosantucci
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

Review 8.  Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications.

Authors:  C A Lyman; T J Walsh
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

Review 9.  The role of active metabolites in drug toxicity.

Authors:  M Pirmohamed; N R Kitteringham; B K Park
Journal:  Drug Saf       Date:  1994-08       Impact factor: 5.606

10.  Bacterial cytosine deaminase mutants created by molecular engineering show improved 5-fluorocytosine-mediated cell killing in vitro and in vivo.

Authors:  Michi Fuchita; Andressa Ardiani; Lei Zhao; Kinta Serve; Barry L Stoddard; Margaret E Black
Journal:  Cancer Res       Date:  2009-06-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.